By Katherine Hamilton
McKesson plans to separate its medical-surgical business into a new company.
The pharmaceutical distributor on Thursday said the new company would be a differentiated medical surgical supply and solutions business.
McKesson expects the spinoff will improve operational focus and improve value for shareholders of both McKesson and the new company. The company focused on expanding its oncology and biopharmaceutical segments during the first quarter, it said.
The medical-surgical solutions segment brought in $2.85 billion of revenue in the fiscal fourth quarter, up 1% from the year before.
"Disciplined capital deployment and portfolio management are hallmarks of our strategy," Chief Executive Officer Brian Tyler said. "We believe that the separation will deliver sustainable long-term growth for both companies."
McKesson posted a 19% increase in revenue to $90.8 billion in the fiscal fourth quarter. It had a profit of $1.26 billion, or $10.01 a share, in the quarter ended March 31, compared with $791 million, or $6.02 a share, the year before.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
May 08, 2025 17:29 ET (21:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。